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Multidrug-Resistant 
Bacteria in 
Southeastern 
Austria
To the Editor: In many parts of 
the world, the proportions of methicil-
lin-resistant  Staphylococcus aureus 
(MRSA), vancomycin-resistant en-
terococci, and extended-spectrum β-
lactamase (ESBL)–producing organ-
isms in the family Enterobacteriaceae 
have increased remarkably during re-
cent years (1). However, proportions 
of antimicrobial drug resistance vary 
substantially at national and regional 
levels. We describe antimicrobial 
drug resistance data for hospitalized 
patients and outpatients in southeast 
Austria.
A total of 690,967 clinical sam-
ples were collected from hospitalized 
patients and outpatients and analyzed 
at the microbiology laboratory of the 
Medical University of Graz during 
1997–2006.  Selected for resistance 
surveillance were nonduplicate iso-
lates of S. aureus, Enterococcus fae-
cium, E. faecalis, Escherichia coli, 
and Klebsiella spp. Antibiotic suscep-
tibilities were determined by using 
disk diffusion and the VITEK2 system 
(bioMérieux, Marcy l’Etoile, France) 
with speciﬁ  c susceptibility test cards. 
Etest (AB Biodisk, Solna, Sweden) 
was used to conﬁ  rm results. Test re-
sults were interpreted according to the 
recommendations of the Clinical and 
Laboratory Standards Institute (2).
During the study period, the pro-
portion of patients with MRSA re-
mained stable (2.5%–4.9%) (Figure, 
panel A). The prevalence of MRSA 
among invasive S. aureus isolates 
ranges between 0.5% and 44.4% in 
European countries and has increased 
in recent years (3). We found MRSA 
predominantly in samples from hos-
pitalized patients (median 72.1%); 
however, the incidence of communi-
ty-acquired MRSA increased slightly 
during recent years, similar to that of 
other central European countries (4). 
Vancomycin resistance was not noted 
during the study period; however, 4 
vancomycin-intermediate MRSA iso-
lates were noted in 2004, 2005, and 
2006, in concordance with the sporad-
ic occurrence of MRSA with interme-
diate susceptibility to glycopeptides 
recently reported for other European 
countries (3).
The percentage of patients with 
vancomycin-resistant E. faecium and 
E. faecalis was low (median 0.4%) 
(Figure, panel A). In total, 10 E. fae-
cium and 4 E. faecalis isolates with re-
sistance to vancomycin were reported; 
most were from hospitalized patients. 
As in most European countries, hu-
man infections due to glycopeptide-
resistant enterococci remain rare in 
Austria, although a high proportion of 
glycopeptide-resistant E. faecium was 
reported recently from animals used in 
food production (5).
Among E. coli isolates, no ESBL 
producers were noted in 1997. From 
1998 through 2002,  proportions of 
ESBL-producing E. coli were 0.06%–
0.13%, which corresponds to 3–6 iso-
lates per year. A subsequent increase 
of ESBL-producing E. coli isolates 
was noted, from 19 (0.3%) in 2003 to 
148 (2.4%) in 2006 (Figure, panel B). 
Most (67%) ESBL-producing isolates 
found during 2003–2006 originated 
from community-acquired urinary 
tract infections. Resistance of E. coli 
to carbapenems was not reported dur-
ing the study period. Among Klebsiella 
spp. isolates, 2 (0.2%) ESBL produc-
ers were observed during 1997. From 
1998 through 2004, the prevalence of 
Figure. A) Proportion of methicillin resistance in Staphylococcus aureus and vancomycin 
resistance in Enterococcus faecium and E. faecalis in southeastern Austria, 1997–2006. 
B) Proportion of extended-spectrum β-lactamase–producing (ESBL) Escherichia coli and 
Klebsiella spp. in southeastern Austria, 1997–2006. LETTERS
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ESBLs among Klebsiella spp. ranged 
between 0.6% and 1.6%. In 2005 and 
2006, the rate of ESBL-producing 
Klebsiella spp. increased to 3.8% (44 
isolates) and 4.5% (55 isolates), re-
spectively, and originated mainly from 
intensive care units (Figure, panel B). 
In 2005, a single Klebsiella pneumoni-
ae isolate showed reduced susceptibil-
ity to imipenem (MIC 2 μg/mL) and 
to meropenem (MIC 4 μg/mL) and 
resistance to ertapenem (MIC >16 
μg/mL). Nevertheless, production of 
ESBL by Enterobacteriaceae organ-
isms is still rare in southeast Austria 
compared with other European coun-
tries (6). However, a dramatic increase 
of ESBL-producing E. coli and Kleb-
siella spp. has been observed during 
recent years. 
The increase of ESBL-producing 
E. coli isolates in outpatients with uri-
nary tract infections leads to serious 
treatment problems. Results from a 
recent study indicate that the increase 
of ESBL-producers in southeast Aus-
tria is caused mainly by the emer-
gence of CTX-M–type ESBLs, which 
are increasingly being isolated from 
outpatients (7). The K. pneumoniae 
isolate found in 2005 represents the 
ﬁ  rst ESBL-producing isolate not sus-
ceptible to carbapenems reported from 
Austria. Development of resistance 
to carbapenems in Enterobacteria-
ceae organisms has been reported in-
creasingly, which substantially limits 
treatment options for persons with 
multidrug-resistant gram-negative in-
fections (8).
Our data show insigniﬁ  cant 
changes in prevalence of MRSA and 
vancomycin-resistant enterococci 
in southeast Austria during the past 
decade but an alarming increase of 
multidrug-resistant ESBL-producing 
E. coli and Klebsiella spp. isolates in 
recent years. Detection of an ESBL-
producing K. pneumoniae isolate with 
reduced susceptibility to carbapenems 
shows that pathogens with new mech-
anisms of resistance are emerging in 
this region.
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Osteomyelitis of 
Parietal Bone in 
Melioidosis 
To the Editor: In Europe and the 
United States, melioidosis is a rare 
disease, with no cases reported thus 
far from Slovenia. However, it is a 
relatively common disease in certain 
areas of Southeast Asia and northern 
Australia. Potentially fatal, this dis-
ease is caused by the gram-negative 
bacillus  Burkholderia pseudomallei, 
an environmental organism found in 
the soil and water of disease-endemic 
areas. Human infections are mostly ac-
quired through percutaneous inocula-
tion during contact with contaminated 
water and soil, although inhalation is 
also a recognized route of acquisition 
(1). Heavy monsoon rain is associated 
with severe disease course (2). Melioi-
dosis was reported in some persons in-
jured in the Tsunami in 2004 (3). The 
disease has a wide spectrum of signs 
and symptoms (4). Osteomyelitis is a 
rare manifestation. It occurs in <5% of 
cases and is a clinical challenge to di-
agnose and treat (1,4,5).
We describe a case of melioidosis 
in a previously healthy, 40-year-old 
Slovenian man. The patient had been 
working as a basketball trainer in Jor-
dan for the previous 12 months and 
was traveling to Brunei in mid-summer 
2006, 14 days before the illness start-
ed. While visiting Brunei, he sustained 
a minor head trauma when he hit his 
head on a night table at the hotel. Ten 
days later, high-grade fever up to 40°C 
developed, without any other signs or 
symptoms of disease. After returning 
to Jordan, the patient was admitted to 
a local hospital and received different 
antimicrobial agents without any im-
provement of his medical condition. 
After 6 weeks of unsuccessful treat-
ment, he decided to continue medical 
treatment in Slovenia.
On admission to our hospital, he 
reported headache and persistent high 
fever of 6 weeks’ duration. Physi-